Case Report: Simultaneously Induced Neutropenia and Hemolysis After a Single Metamizole Dose
Related Experiment Video
Updated: Aug 5, 2025
MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data
Published on: February 7, 2025
Raphael Allgaier1, Arne Kandulski2, Karsten Gülow2
1Department of Internal Medicine II, Cardiology, University Medical Center Regensburg, Regensburg, Germany. Raphael.Allgaier@ukr.de.
Background And Objective:
Metamizole is a non-opioid ampyrone sulfonate compound with potent analgesic, antipyretic, and spasmolytic effects. Agranulocytosis is a rare life-threatening complication of metamizole.
Case:
Here, we present the case of a 62-year-old patient who developed agranulocytosis as well as hemolysis after a single administration of metamizole.
Conclusion:
This case illustrates the inherent allergic potential of metamizole and its effects on different hematopoietic cell types.
Insights
Metamizole, a potent analgesic, can rarely cause agranulocytosis and hemolysis. This case highlights metamizole
Area of Science:
- Pharmacology
- Hematology
- Toxicology
Background:
- Metamizole is a widely used non-opioid analgesic, antipyretic, and spasmolytic agent.
- Agranulocytosis is a rare but severe adverse effect associated with metamizole use.
Observation:
- A 62-year-old patient experienced both agranulocytosis and hemolysis.
- These severe reactions occurred after a single dose of metamizole.
Findings:
- This case demonstrates the potential for metamizole to induce serious allergic reactions.
- Metamizole can affect multiple hematopoietic cell lineages, leading to diverse blood disorders.
Implications:
- Clinicians should be aware of metamizole's potential for severe hematologic toxicity.
- This case underscores the importance of monitoring patients for adverse reactions to metamizole.
